PPIs appear to increase the risk of contracting COVID-19

There's a dose-response relationship linked to acid suppression, researchers say

Patients taking PPIs are more likely to be diagnosed with COVID-19 than the general population, a study of 90,000 Americans has found.

The study, based on an online survey conducted from May to June, found once-daily PPI treatment was associated with a 115% increased risk of a COVID-19 diagnosis.

And patients on twice-daily PPIs had a threefold increased risk of having COVID-19.

As a potential explanation, the researchers from the Cedars-Sinai Medical Center in California, pointed to research into SARS-CoV-1 conducted in 2004 that found acidic conditions rendered the virus inactive.